Takeda is executing another round of layoffs, cutting 243 roles in the United States. The company is preparing for an upcoming patent loss on depression drug Trintellix.

GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotech’s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.

As it inches closer to FDA submissions for its psychedelic drug candidate, Definium Therapeutics is laying the groundwork for a future launch with an educational push about the pharmaceutical potential of LSD.

The U.S. Supreme Court will hear a case involving the “skinny label” practice of generic drugmakers, with its review particularly relating to Hikma’s marketing of its generic version of Amarin’s Vascepa.

As the U.S. government intensifies efforts to acquire Greenland, President Donald Trump has responded to European pushback with a new, targeted tariff threat that risks upending the trade deal reached with the EU last summer.

Five weeks after telling investors to expect a revenue decline in 2026, Pfizer has found a quick funding fix, selling off its stake in GSK’s ViiV Healthcare. The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms of the agreement, […]